MesenFlow

Translational medicine in action, and validation for the MesenFlow strategy. Mesenchymal factors regulate human CD16+ monocyte function in chronic inflammation and cancer. twitter.com/NatureComms/st…

MesenFlow Technologies is proud to be part of a study on circadian rhythms in leukocyte trafficking, published in @ImmunityCP. What a fantastic way to end the year. We wish our friends and colleagues a Happy New Year for 2019! cell.com/immunity/pdfEx…

Commentary on the publication in Nature Comms, with the founders of MesenFlow Technologies. Applying powerful and deliverable translational technologies to cancer therapy. sciencedaily.com/releases/2018/…

Valdiating a translational approach in the treatment of cancer & chronic inflammation. A radio interview with author Adama Sidibe about a recent publication in Nature Comms. Further validation of the MesenFlow strategy (In French). rts.ch/play/radio/cqf… via @RadioTeleSuisse

@stuartacook1 Good to see you on Twitter. All a bit new to me. Maybe this link is of interest to you in CV disease and chronic inflammation? Regards, Paul twitter.com/NatureComms/st…

Angiogenic factor-driven inflammation promotes extravasation of human proangiogenic monocytes to tumours go.nature.com/2DHO56P

I'm going to CPhI Worldwide, 24-26 Oct, Messe Frankfurt, Germany. Join me! invt.io/8F062F224C @CPhIWW #cphiww

Setting up our stand. MesenFlow Technologies is at the ESM-EVBO 2017 conference in Geneva. Looking forward to seeing you there!

MesenFlow will be at the ESM-EVBO 2017, May 29-June 1st 2017, Geneva, Switzerland esm-evbo2017.org

Our Services

Good news with Venture Kick! venturekick.ch/index.cfm?CFID…

Just setting up my Twitter. #myfirstTweet